Context Therapeutics
€2.2
29
+€0.16+7.84% Wednesday 06:19
Statistics
Day High
2.2
Day Low
2.2
52W High
3.12
52W Low
0.44
Volume
-
Avg. Volume
-
Mkt Cap
202.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.1125
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-50.23MNet Income
Analyst Ratings
$5.31Average Price Target
The highest estimate is 6.83.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 6K9.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Puma Biotechnology
PBYI
Mkt Cap351.05M
Macrogenics
MGNX
Mkt Cap195.12M
TG Therapeutics
TGTX
Mkt Cap5.35B
Kura Oncology
KURA
Mkt Cap891.41M
Array Technologies
ARRY
Mkt Cap1.12B
Incyte
INCY
Mkt Cap19.09B
About
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
Mr. Martin A. Lehr
Employees
12
Country
US
ISIN
US21077P1084
WKN
000A3CWBU
Listings
0 Comments
Share your thoughts
FAQ
What is Context Therapeutics stock price today?▼
The current price of 6K9.F is €2.2 EUR — it has increased by +7.84% in the past 24 hours. Watch Context Therapeutics stock price performance more closely on the chart.
What is Context Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Context Therapeutics stocks are traded under the ticker 6K9.F.
Is Context Therapeutics stock price growing?▼
6K9.F stock has risen by +0% compared to the previous week, the month change is a -9.09% fall, over the last year Context Therapeutics has showed a +315.09% increase.
What is Context Therapeutics market cap?▼
Today Context Therapeutics has the market capitalization of 202.13M
When is the next Context Therapeutics earnings date?▼
Context Therapeutics is going to release the next earnings report on May 13, 2026.
What were Context Therapeutics earnings last quarter?▼
6K9.F earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.09 EUR resulting in a -33.58% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Context Therapeutics revenue for the last year?▼
Context Therapeutics revenue for the last year amounts to 0 EUR.
What is Context Therapeutics net income for the last year?▼
6K9.F net income for the last year is -50.23M EUR.
How many employees does Context Therapeutics have?▼
As of April 06, 2026, the company has 12 employees.
In which sector is Context Therapeutics located?▼
Context Therapeutics operates in the Health Care sector.
When did Context Therapeutics complete a stock split?▼
Context Therapeutics has not had any recent stock splits.
Where is Context Therapeutics headquartered?▼
Context Therapeutics is headquartered in Philadelphia, US.